SEC Form 4 · accession 0000899243-18-023647
G1 Therapeutics, Inc. · GTHX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jay Strum
Officer — Chief Scientific Officer
Period of report
Aug 29, 2018
Accepted (ET)
Aug 31, 2018 · 4:20 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001560241
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Comomon StockF1 | Aug 29, 2018 | S | 600 | $58.403 | D | 57,969 | D | |
| Comomon StockF2 | Aug 29, 2018 | S | 3,500 | $59.10 | D | 54,469 | D | |
| Comomon StockF3 | Aug 29, 2018 | S | 700 | $60.004 | D | 53,769 | D | |
| Comomon StockF4 | Aug 29, 2018 | S | 200 | $61.00 | D | 53,569 | D | |
| Comomon StockF5 | Aug 30, 2018 | S | 500 | $59.266 | D | 53,069 | D | |
| Comomon StockF6 | Aug 30, 2018 | S | 4,500 | $60.054 | D | 48,569 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price represents the weighted average price with a low of $57.79 and a high of $58.695. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes 1 through 6.
- F2The price represents the weighted average price with a low of $58.80 and a high of $59.72.
- F3The price represents the weighted average price with a low of $59.88 and a high of $60.14.
- F4The price represents the weighted average price with a low of $60.95 and a high of $61.05.
- F5The price represents the weighted average price with a low of $58.65 and a high of $59.58.
- F6The price represents the weighted average price with a low of $59.68 and a high of $60.33.